Investor Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies reported weak Q3FY26 results with revenue falling 22% YoY to ₹21.11 Cr and PAT declining 43% to ₹3.10 Cr, while 9MFY26 revenue was down 10% to ₹76.09 Cr. Management attributed the decline to Christmas-period shipment delays (10-12% of quarterly topline deferred to Q4), weak European demand, and price-led competition that hit realisations. EBITDA margin compressed to 31.9% from 36.6% YoY, reflecting the pricing pressure. On the growth side, the new pilot facility is now operational, Block 7 commercial production is targeted for H1FY27 (~₹20 Cr capex), and the Japanese CRAMS engagement continues to advance. Management positioned FY26 as a 'year of consolidation' and guided for gradual improvement in FY27 driven by new product development and CRAMS traction.
Near-term earnings disappointment with sharp revenue and margin contraction is likely already priced in given the stock trades near 52-week lows (₹424 vs ₹950 high). However, the FY27 visibility on pilot facility ramp-up, Block 7 commissioning, and CRAMS traction provides a constructive medium-term story; investors should watch Q4 execution for the deferred shipments and signs of demand recovery in Europe.